Logo

VantAI and BMS Partner to Expedite Molecular Glue Drug Discovery Through Artificial Intelligence

Share this
VantAI

VantAI and BMS Partner to Expedite Molecular Glue Drug Discovery Through Artificial Intelligence

Shots:

  • VantAI and BMS have signed a strategic collaboration for the discovery of new molecular glues for targeting therapeutic areas of interest
  • VantAI will receive ~$674M in milestone payments which include discovery, development, clinical, regulatory, and sales plus tiered royalties with an option of expansion to additional therapeutic programs
  • The collaboration will utilize BMS’ expertise in targeted protein degradation for the discovery and development of new small molecules and VantAI’s geometric deep learning technology, Protein-Contact-First (PCF) approach that makes the complex chemical design challenge simple to produce solutions with optimized parameters like potency, selectivity, and molecule size 

Ref: VantAI | Image: VantAI

Related News:- Boehringer Ingelheim Entered into a Research Agreement with VantAI to Identify Novel Protein Degraders

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions